Pierre Fabre Set To Shake Up EU Melanoma Market

Having just got the nod for the combination of Braftovi and Mektovi, the French company believes the strength of its overall survival data will see the therapy successfully compete with other BRAF/MEK combos and immunotherapies for melanoma.

Airplanes
Pierre Fabre lines up launches for melanoma combo • Source: Shutterstock

With approval from the European Commission secured in September for the combination of its BRAF inhibitor Braftovi (encorafenib) and MEK inhibitor Mektovi (binimetinib), Pierre Fabre Group is now focusing on access for its metastatic melanoma therapy in a crowded market.

The combo got the green light in Europe last month based on data from the Phase III COLUMBUS trial in...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip